Compare BWIN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWIN | ZLAB |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | China |
| Employees | 5020 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | BWIN | ZLAB |
|---|---|---|
| Price | $26.22 | $18.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $30.43 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 2.0M | 968.1K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $36.36 | $9.75 |
| Revenue Next Year | $10.82 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $15.88 | $15.96 |
| 52 Week High | $43.25 | $41.20 |
| Indicator | BWIN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 69.92 | 45.85 |
| Support Level | $20.42 | $16.78 |
| Resistance Level | $26.74 | $19.41 |
| Average True Range (ATR) | 1.49 | 0.68 |
| MACD | 0.86 | 0.21 |
| Stochastic Oscillator | 98.08 | 55.79 |
The Baldwin Insurance Group Inc is an insurance distribution company operating in the United States. The company provides commercial risk management, employee benefits, private risk management, and personal insurance solutions. It operates through three segments: Insurance Advisory Solutions, which focuses on commercial risk management and employee benefits; Underwriting, Capacity & Technology Solutions, which includes managing general agency operations, reinsurance brokerage, captive management, and technology-enabled insurance products; and Mainstreet Insurance Solutions, which offers personal, commercial, and life and health insurance products through community-based distribution channels.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.